You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

nAMD

Showing 1 - 25 of 130
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD Trial (LX109)

Not yet recruiting
  • To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD
  • (no location specified)
Sep 1, 2023

Russian Registry of Patients With nAMD

Terminated
  • Neovascular Age-Related Macular Degeneration
  • nAMD
  • (no location specified)
Jan 16, 2023

Neovascular Age-related Macular Degeneration(nAMD) Trial in Shanghai, Tianjin (HG202)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration(nAMD)
  • HG202
  • Shanghai, Shanghai, China
  • +1 more
Sep 4, 2023

Age-Related Macular Degeneration Trial in Malvern, Saint Albans (BBC1501)

Not yet recruiting
  • Age-Related Macular Degeneration
  • Malvern, Victoria, Australia
  • +1 more
Apr 5, 2023

Neovascular Age-related Macular Degeneration (nAMD) Trial in Abilene (OCU-10-C-110 for Injection)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration (nAMD)
  • OCU-10-C-110 for Injection
  • Abilene, Texas
    Retina Research Institute of Texas
Jun 6, 2023

Neovascular Age-related Macular Degeneration Trial (AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • AXT107 Low Dose
  • +2 more
  • (no location specified)
May 5, 2023

Neovascular Age-related Macular Degeneration Trial in Shanghai (LX102-C01 Injection)

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • LX102-C01 Injection
  • Shanghai, China
    Shanghai General Hospital, Shanghai Jiao Tong University School
Apr 14, 2023

Age-Related Macular Degeneration Trial in Beijing (KH631)

Not yet recruiting
  • Age-Related Macular Degeneration
  • Beijing, China
    Beijing Tongren Hospital, Capital Medical University
Jan 3, 2023

Neovascular Age-related Macular Degeneration Trial in Katy, Norfolk (SKG0106)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • SKG0106
  • Katy, Texas
  • +1 more
Aug 15, 2023

Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Austin (AIV007)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Austin, Texas
    Retina Consultants of Austin
Jan 16, 2023

Neovascular Age-related Macular Degeneration (nAMD) Trial (AR-14034 SR implant lower dose, Aflibercept Injection, Sham

Not yet recruiting
  • Neovascular Age-related Macular Degeneration (nAMD)
  • AR-14034 SR implant lower dose
  • +3 more
  • (no location specified)
Mar 3, 2023

Early Real-world Evidence of Brolucizumab in Neovascular

Completed
  • Neurovascular Age-related Macular Degeneration
    • Bangalore, India
    • +3 more
    Apr 26, 2023

    Brolucizumab in Pre-treated nAMD in the Real-world Setting

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Brolucizumab
    • (no location specified)
    Aug 8, 2022

    Learn More About How Well Aflibercept 8 mg Works in Treating

    Not yet recruiting
    • Visual Impairment
    • +2 more
    • Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
    • Multiple Locations, Australia
    • +5 more
    Oct 4, 2023

    Neovascular Age-related Macular Degeneration Trial (RRG001)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • (no location specified)
    Nov 15, 2023

    Neovascular (Wet) Age-related Macular Degeneration (nAMD) Trial (EXG102-031)

    Not yet recruiting
    • Neovascular (Wet) Age-related Macular Degeneration (nAMD)
    • EXG102-031
    • (no location specified)
    Jun 13, 2023

    Age-Related Macular Degeneration Trial (MG-O-1002, Placebo)

    Not yet recruiting
    • Age-Related Macular Degeneration
    • (no location specified)
    May 20, 2022

    Fluid Resolution and Effectiveness of Brolucizumab for nAMD in

    Recruiting
    • Neovascular Age-related Macular Degeneration (nAMD)
    • Funchal, Portugal
    • +11 more
    Jun 9, 2022

    Single Injection of Faricimab for nAMD With Persisting Fluid

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • Glostrup, Denmark
      Miklos Schneider
    Nov 3, 2023

    Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) Trial (aflibercept 8 mg PFS)

    Not yet recruiting
    • Diabetic Macular Edema (DME)
    • Neovascular Age-Related Macular Degeneration (nAMD)
    • aflibercept 8 mg PFS
    • (no location specified)
    Aug 3, 2023

    Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept Ophthalmic
    • IBI302
    • Suzhou, Jiangsu, China
      Innovent Biologics (Suzhou) Co,Ltd.
    Jul 25, 2023

    Neovascular Age-related Macular Degeneration Trial in Beijing (IBI333)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • IBI333
    • Beijing, Beijing, China
      Peking Union Medical College Hospital, Chinese Academy of Medica
    Nov 28, 2022

    Wet Age-related Macular Degeneration Trial in Chengdu (MW02, Lucentis)

    Recruiting
    • Wet Age-related Macular Degeneration
    • Chengdu, Si Chuan, China
      West China Hospital of Sichuan University
    Mar 17, 2022

    Macular Degeneration, Wet, Metamorphopsia Trial

    Recruiting
    • Macular Degeneration, Wet
    • Metamorphopsia
      • Cuneo, Piedmont, Italy
        Ospedale Santa Croce
      Sep 20, 2022

      AMD, nAMD, Wet Age-related Macular Degeneration Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®))

      Recruiting
      • AMD
      • +5 more
      • RGX-314 Dose 1
      • +2 more
      • Encino, California
      • +16 more
      Jun 2, 2022